The FDA approved a new drug for high blood pressure, Tekturna (aliskiren), a first-in-class product partnered between Speedel Group and Novartis AG. (BioWorld Today)
Microbia Inc. raised $50 million in private equity to push product development, with a particular focus on multiple Phase II studies of its two lead products. (BioWorld Today)
Microbia Inc. raised $50 million in private equity to push product development, with a particular focus on multiple Phase II studies of its two lead products. (BioWorld Today)
WASHINGTON - In response to a bill that would require the Department of Health and Human Services to negotiate directly with the manufacturers of single-source drugs without therapeutic equivalents covered under Medicare Part D, the Biotechnology Industry Organization (BIO) this week issued concrete numbers demonstrating savings realized by seniors under the existing free-market framework. (BioWorld Today)
WASHINGTON - In response to a bill that would require the Department of Health and Human Services to negotiate directly with the manufacturers of single-source drugs without therapeutic equivalents covered under Medicare Part D, the Biotechnology Industry Organization (BIO) this week issued concrete numbers demonstrating savings realized by seniors under the existing free-market framework. (BioWorld Today)
